Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,705.00
Bid: 1,650.00
Ask: 1,710.00
Change: 0.00 (0.00%)
Spread: 60.00 (3.636%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Watch the virus' reproduction rate

Mon, 03rd Feb 2020 11:25

* STOXX 600 flat, FTSE 100 up 0.6%
* Ingenico top riser in Europe on Worldline takeover offer
* UK manufacturing ends longest decline since financial crisis

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters and anchored today by Joice Alves. Reach her on Messenger to share your
thoughts on market moves: joice.alves.thomsonreuters.com@reuters.net



WATCH THE VIRUS' REPRODUCTION RATE (1124 GMT)
A key indicator for stocks owners is the pace by which the coronavirus spreads, Jefferies
analysts wrote in equity strategy note this morning.
Any indication that the reproduction rate is accelerating or decelerating versus a roughly
50% growth rate per day is something worth considering, they argue.
"Presumably, if the rate rises above the line the markets should be more concerned and
vice-versa", they write.
Here's their chart:
(Julien Ponthus)
*****



WHY UTILITIES ARE SO HOT (1037 GMT)
With a nearly 10% relative outperformance so far in 2020 utilities are becoming a
hot spot for investors.
It may be for their defensive qualities and bond-like features that utilities are getting
attention, as virus fears slow economic growth expectations, but it also looks like the
transition to a greener world is going to inject new life into this investment space.
For Barclays, utilities are now a growth sector.
"We believe the EU's and UK's ambitious targets to achieve 'Net Zero' emissions by 2050 are
achievable, placing utilities at the forefront of a 3.7 trillion euro investment boom, and
making the sector a key beneficiary of the coming industrial revolution," the UK bank writes.
Yet the transition is not going to be pain-free and while Barclays sees winners, there will
be losers too.
Among the latter it sees gas distribution infrastructure and power transmission solar
networks, while among the former are renewable generation, power infrastructure, gas
transmission infrastructure and hydrogen.
For more on utilities:
Utilities: flying like a FANG
Davos: Watch those utilities

(Danilo Masoni)
*****


THE CURSED AUTO SECTOR: CORONAVIRUS DENTS PRODUCTION (1015 GMT)
A total of 362 people have succumbed to the deadly virus, leaving the SARS comparison far
behind and businesses worried about supply chain disruptions and falling demand.
Autos, which had a rough 2019, are no exception.
With Wuhan completely shut and the rest of China in extended Lunar New Year holidays, Citi
analysts expect automakerts to take hit with VW being most exposed in terms of production.
Citi sees 40,000 per day reduction in vehicle production in China -- "assuming two weeks of
meaningful impact, this could imply c.1.5-2% drag on annual production and retail sales".
Car parts supplier Valeo and OEMs Daimler and Renault are
seen taking a bigger hit from the output declines. The bank has a "sell" rating on all three of
them.
This chart clearly shows how autos have been dented the most by virus fears:

Autos are clearly becoming the stock market scapegoat of the coronavirus scare here in
Europe. UBS analysts say among the two big underperformers with the biggest exposure to the
epidemic in China, autos are a much bigger concern than luxury stocks.
"On a multi-month view, our Luxury analysts are much more bullish than are our Auto
analysts", UBS writes.
On the big scheme of things, European industrials are holding up, they note.

Another interesting thing is that they are not ready to give up their structurally long
stance on Chine equities.
They do acknowledge however that given the gravity of the situation, they are looking for
"the right hedges".

(Thyagaraju Adinarayan and Julien Ponthus)
*****

THE HARDER THE FALL, THE BIGGER THE BOUNCE (0928 GMT)
It may sound simplistic but in essence that's how many see the opportunity created by the
coronavirus outbreak in China.
Among these is JPMorgan, who believes stocks will make further all-time highs before the
next U.S. recession strikes.
"The Coronavirus outbreak is likely to keep markets under pressure near term. That said, the
more the markets fall in the short term, the more they are likely to rebound once the number of
cases appears to be peaking," strategists at the U.S. bank led by Mislav Matejka say.
"Fundamental backdrop is supportive, in our view, and the fallout from the outbreak is
unlikely to hurt activity prints over the medium term," they add.

(Danilo Masoni)
*****

OPENING SNAPSHOT: INGENICO UP, WORLDLINE DOWN (0834 GMT)
European bourses opened in positive territory with Ingenico as expected topping the Stoxx
600 index after Worldline agreed to buy the French payments company in a deal
which would create a new European champion in the sector.
It is also worth noting that Ingenico shares are trading well below Worldline's 123.1 euro
per share offer price. Worldline shares meanwhile are sliding 5%.
Other top movers in Europe are Siemens Healthineers down 4% and Julius Baer
off 4%, both reported lower profits.
Ryanair shares are jumping 3.6% after company third quarter revenues beat estimates.

(Joice Alves)
****


ON OUR RADAR: UK, DRUGMAKERS, RYANAIR, WORLDLINE (0755 GMT)
Futures point to a higher open in Europe after Brexit and reports on Saturday that Boris
Johnson would consider a looser trade agreement with the European Union, similar to the bloc's
ties with Australia, rather than follow EU rules to reach a closer deal.
Johnson is expected to give a speech on trade today. Traders are also expecting some
eurozone and UK PMI numbers, which will be released this morning.
In terms of single stocks, Siemens Healthineers shares are down 6.5% in early
Frankfurt trade after it said Q1 profit fell on higher diagnostic gear costs
Meantime, UK drugmaker GlaxoSmithKline is also on the radar after it said it is
collaborating with the Coalition for Epidemic Preparedness Innovations to develop a vaccine for
the coronavirus outbreak.
In terms of M&A, traders see payments company Ingenico shares rallying 17% after
Worldline agreed to buy its French peer in a deal which would create a new European
champion in the sector.
Ryanair shares are seen 1-2% higher after 3Q revenues beat estimates but the company
said it may have to push back its long-term target of flying 200 million passengers per year by
as much as two years due to delays in the delivery of Boeing's <BA.N 737> MAX jet.
Some other earning results could move stocks: Swedish telecoms operator Tele2 Q4
earnings beat forecast company launched a new restructuring programme.
Julius Baer is seen 2% lower as it said it will cut 300 jobs after 2019 profit
drop.

Other corporate headlines:
Sri Lanka to probe graft accusations over Airbus deal
Imperial Brands names Stefan Bomhard CEO
(Joice Alves)
*****


EUROPEAN STOCKS SEEN HIGHER (0650 GMT)
European bourses are expected to open higher this morning as investors get some relief from
the fact that the UK left the euro zone ending years of uncertainty around the Brexit outcome.
Fears from Asia will likely put a brake on the enthusiasm. As traders in Asia returned from
a week-long Lunar Year break, shares across the region and global commodity prices stumbled on
concerns that the coronavirus epidemic will hit demand in the world's second-largest economy.
Investors will also have their eyes on PMI data from the euro zone, Germany, France, Italy,
Netherlands and Spain that will be released this morning.
Back in the UK, today's PMI data will likely see little market reaction as services PMI due
Wednesday matters more for the economy.
Financial spreadbetters at IG expect London's FTSE to open 15 points higher at 7,286,
Frankfurt's DAX to open 21 points up at 12,981 and Paris' CAC to open 12 points higher at
5,806.

(Joice Alves)
*****?



(Reporting by Danilo Masoni, Joice Alves, Julien Ponthus and Thyagaraju Adinarayan)

More News
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.